Guideline:
The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer
Bibliographic Source(s)
- American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]
Guideline Status
This is the current release of the guideline.
Guideline Category
Risk Assessment
Screening
Intended Users
Allied Health Personnel
Physicians
Guideline Objective(s)
To review current publications and expert opinion on the screening of women at high risk for breast cancer with magnetic resonance imaging of the breast (MRIB)
Target Population
Women at high risk for breast cancer
Interventions and Practices Considered
Screening of Women at High Risk for Breast Cancer
- Magnetic resonance imaging of the breast (MRIB) as an adjunct to:
- Mammography
- Clinical breast examination
- Ultrasonography
Major Outcomes Considered
Sensitivity and specificity of diagnostic tests
Methods Used to Collect/Select Evidence
Searches of Electronic Databases
Searches of Unpublished Data
Description of Methods used to Collect/Select the Evidence
Not stated
Number of Source Documents
Not stated
Methods Used to Assess the Quality and Strength of the Evidence
Expert Consensus (Committee)
Rating Scheme for the Strength of the Evidence
Not applicable
Methods Used to Analyze the Evidence
Review
Description of the Methods Used to Analyze the Evidence
The Consensus Committee of the American Society for Breast Disease established a subcommittee working group which reviewed current publications and expert opinion on the screening of women at high risk for breast cancer with magnetic resonance imaging of the breast (MRIB).
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Not stated
Rating Scheme for the Strength of the Recommendations
Not applicable
Cost Analysis
A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation
Peer Review
Description of Method of Guideline Validation
The recommendations were distributed by e-mail to more than 600 members of the American Society of Breast Disease (ASBD) who were invited to comment. The recommendations were then revised to reflect this peer review.
Major Recommendations
- Magnetic resonance imaging of the breast (MRIB) is an adjunct to mammography clinical breast examination and ultrasonography for breast cancer detection in women at high risk of breast cancer based on family history or BRCA mutations.
- MRIB is not recommended for breast cancer screening in the general population.
- Although published studies have evaluated yearly screening in conjunction with mammography clinical breast examination and in some cases ultrasonography the appropriate screening interval for MRIB is not yet determined.
- At this time there are no data on the use of MRIB for breast cancer screening of women at high risk based on personal history of breast cancer previous chest irradiation lobular carcinoma in situ atypical hyperplasia or mutations other than BRCA.
- Limitations of MRIB are related to technical professional and biological factors as well as availability. Standards related to equipment scanning protocols interpretation MRI-guided biopsies and MRI-guided needle localization are presently under development by the American College of Radiology and other societies. Implementation of these performance standards is expected to continually increase the importance of MRIB.
- Women should be advised of the benefits and limitations of MRIB.
- The guideline committee supports and encourages prospective clinical trials of MRIB for surveillance of women at high risk for breast cancer.
Clinical Algorithm(s)
None provided
Type of Evidence supporting the Recommendations
The type of evidence supporting the recommendations is not specifically stated.
Potential Benefits
Improved screening of women at high risk for breast cancer based on family history or BRCA mutations
Potential Harms
Not stated
Description of Implementation Strategy
An implementation strategy was not provided.
IOM Care Need
Living with Illness
Staying Healthy
IOM Domain
Effectiveness
Patient-centeredness
Bibliographic Source(s)
- American Society of Breast Disease. The use of magnetic resonance imaging of the breast (MRIB) for screening of women at high risk of breast cancer. Dallas (TX): American Society of Breast Disease; 2004 Jun 28. 5 p. [40 references]
Adaptation
Not applicable: The guideline was not adapted from another source.
Source(s) of Funding
American Society of Breast Disease
Guideline Committee
Expert Committee on Screening of Women at High Risk of Breast Cancer
Composition of Group that Authored the Guideline
Committee Members: Amy P. Early MD Buffalo Medical Group Williamsville New York Chair; Julio A. Ibarra MD Orange Coast Memorial Medical Center Fountain Valley California; Kenneth H. Eckert Jr. MD Kaleida Breast Center Women and Children’s Hospital Buffalo New York; David M. Euhus MD University of Texas Southwestern Medical Center Dallas Texas; Steven E. Harms MD University of Arkansas Little Rock Arkansas; Richard W. Reitherman MD Newport Diagnostic Center La Canada California; Eva Rubin MD Montgomery Radiology Associates Montgomery Alabama
Financial Disclosures/Conflicts of Interest
Not stated
Guideline Status
This is the current release of the guideline.
Guideline Availability
Electronic copies: Not available at this time.
Print copies: Available from the American Society of Breast Disease PO Box 140186 Dallas Texas 75214; Phone: (214) 368-6836
Availability of Companion Documents
None available
Patient Resources
None available
NGC STATUS
This NGC summary was completed by ECRI on August 16 2004. The information was verified by the guideline developer on September 14 2004.
COPYRIGHT STATEMENT
This NGC summary is based on the original guideline which is subject to the guideline developer's copyright restrictions.
NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop produce approve or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies relevant professional associations public or private organizations other government agencies health care organizations or plans and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .
NGC AHRQ and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC AHRQ or its contractor ECRI Institute and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.